text
stringlengths 0
197k
|
|---|
In this study, the diagnostic importance of changes in NLR, PLR, and PIV values in the preoperative and postoperative periods will be investigated in detecting complications that develop in the perioperative period before discharge in patients who underwent LSG. conditions: Morbid Obesity conditions: Laparoscopic Sleeve Gastrectomy conditions: Post Operative Complicaiton studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 159 type: ACTUAL name: Laparoscopic Sleeve Gastrectomy measure: Complication prediction after LSG with complete blood cell parameters sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Kahramanmaras SIU city: Kahramanmaraş zip: 46000 country: Turkey lat: 37.5847 lon: 36.92641 hasResults: False
|
<|newrecord|> nctId: NCT06284343 id: 6414 briefTitle: Development and Validation of a Risk Prediction Model for Venous Thromboembolism in Gynecological Cancer Patients Undergoing Systemic Antineoplastic Treatment: The Gynecological Cancer Associated Thrombosis (GynCAT) Study acronym: GynCAT overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-09-30 date: 2026-09-30 date: 2024-02-28 date: 2024-02-28 name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS class: OTHER name: Fondazione Umberto Veronesi briefSummary: Cancer patients are burdened by an increased risk of venous thromboembolism (VTE), which has a significant impact on morbidity and mortality. Existing Risk Prediction Models (RPMs), including the widely accepted Khorana Risk Score (KRS), have some limitations when used in certain tumor site populations, such as gynecological cancers. Notably, gynecological patients exhibit a variable risk of VTE based on their specific tumor sites, with ovarian cancer representing the highest risk. Moreover, currently available RPMs lack validation in a broad gynecological population and may fail to effectively stratify VTE risk.
|
GynCAT is a prospective cohort study that will be conducted on female patients with gynecologic malignancies scheduled for systemic antineoplastic treatment. During the screening phase, symptomatic VTE will be excluded, and KRS will be assessed. Pharmacological thromboprophylaxis will be considered and prescribed at clinical judgement, for patients with a KRS score of 3 or higher. Clinical, hematological, biochemical, coagulation, and genetic variables will be collected. Follow-up will last for the entire duration of the antineoplastic treatment line, and VTE events, bleeding events, and mortality will be recorded.
|
The primary objective is the development and validation of an RPM for VTE in gynecologic cancer patients undergoing systemic antineoplastic treatment. Secondary objectives are evaluation of the predictive value of the identified model, comparing it with existing general oncology RPMs; assessment of its performance in predicting mortality; evaluation of VTE incidence in patients with KRS≥3 receiving thromboprophylaxis; identification of risk factors for bleeding in this patient population.
|
The sample size calculation is based on an estimated VTE incidence of 5% over a mean follow-up of 12 months. Hence, a sample size of at least 1,200 patients in the derivation cohort is considered sufficient for the determination of a risk prediction model incorporating up to six predictor variables. A split-sample method will be used, with two-thirds of the study participants randomly assigned to the model derivation cohort (n=1,200) and one-third (n=600) to an independent validation cohort. The total number of patients recruited in the study will thus be of 1,800. A competing risk survival analysis with Fine \& Gray model will be used to study the association between prognostic variables and VTE occurrence, considering death as a competitive risk. The RPM will be identified through a bootstrap approach to reduce the risk of overfitting. Discrimination power of the RPM will be assessed using time-dependent Receiving Operating Characteristic curve, and model calibration will be evaluated graphically and with the calculation of relative calibration slopes.
|
In conclusion, this prospective cohort study aims to overcome the limitations of current RPMs in gynecologic cancer patients, improving the accuracy of VTE risk stratification in this population. conditions: Cancer-associated Thrombosis conditions: Venous Thromboembolism conditions: Gynecologic Cancer conditions: Ovarian Cancer conditions: Cervix Cancer conditions: Endometrial Cancer conditions: Vaginal Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1800 type: ESTIMATED name: Anticoagulant measure: Venous thromboembolism measure: Bleeding sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione Policlinico Universitario A. Gemelli IRCCS city: Rome zip: 00168 country: Italy lat: 41.89193 lon: 12.51133 hasResults: False
|
<|newrecord|> nctId: NCT06284330 id: STU-2023-0881 briefTitle: CHARGE Study: CHoice ARchitecture Genetic tEsting acronym: CHARGE overallStatus: RECRUITING date: 2024-02-16 date: 2025-03 date: 2025-08 date: 2024-02-28 date: 2024-04-05 name: University of Texas Southwestern Medical Center class: OTHER briefSummary: CHARGE is a hybrid type I feasibility study to compare a choice architecture intervention for cascade genetic testing to usual care. conditions: Hereditary Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 260 type: ESTIMATED name: Enhanced cascade testing measure: Rate of cascade genetic testing measure: Change in probands' family communication about genetic test results as measured by Proband survey measure: Proband's and relative's satisfaction with decision about participating in study measured at approximately 4- 7 months measure: Family functioning as reported by probands and relatives measured by Cancer Family Impact Scale measure: Proband's reaction to intervention materials as measured by proband survey. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UT Southwestern Medical Center status: RECRUITING city: Dallas state: Texas zip: 75390 country: United States name: Sukh Makhnoon, PhD, MS role: CONTACT phone: 214-648-3242 email: Chargestudy@utsouthwestern.edu name: Sukh Makhnoon, PhD, MS role: PRINCIPAL_INVESTIGATOR lat: 32.78306 lon: -96.80667 hasResults: False
|
<|newrecord|> nctId: NCT06284317 id: ETOP 25-23 briefTitle: A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer. acronym: ADOPT-lung overallStatus: NOT_YET_RECRUITING date: 2024-10 date: 2029-10 date: 2030-03 date: 2024-02-28 date: 2024-04-05 name: ETOP IBCSG Partners Foundation class: NETWORK name: AstraZeneca AG Switzerland briefSummary: ADOPT-LUNG is an international, multicentre, open-label randomised phase III trial. Protocol treatment consists of 3-4 cycles of neoadjuvant durvalumab in combination with platinum-based doublet chemotherapy, followed by surgery. Patients with R0 and R1 only resection will be randomised to receive either adjuvant durvalumab for 12 cycles (experimental arm) or observation (control arm). The primary objective of the study is to determine whether additional adjuvant immunotherapy with durvalumab after neoadjuvant chemo-immunotherapy has an effect on disease-free survival (DFS) in patients who do not achieve complete pathological response (pCR) as per local assessment according to the IASLC recommendations. conditions: Non Small Cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 290 type: ESTIMATED name: Adjuvant durvalumab measure: Disease-free survival (DFS) measure: Response rate as per investigator assessment. measure: Proportion of patients undergoing surgery measure: Proportion of patients with surgical outcome R0 and R1 measure: pCR rate measure: Proportion of patients eligible for randomisation measure: Proportion of patients effectively randomised measure: Toxicity according to CTCAE v5.0 measure: DFS in patients with pCR measure: Overall survival (OS) in patients with/without pCR measure: DFS in patients with/without ctDNA clearance measure: Time to recurrence (TTR) in patients with/without pCR measure: Time to treatment discontinuation (TTD) in patients with/without pCR measure: Toxicity according to CTCAE v5.0 measure: Correlation between ctDNA clearance and pathological response measure: Correlation between ctDNA clearance and DFS measure: Correlation between ctDNA clearance and OS measure: Correlation between ctDNA clearance and initial PD-L1 assessment measure: Outcome (OS) measure: Outcome (event-free survival) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06284304 id: N22DES briefTitle: A Pilot Study of Dose dE-eScalaTion IN prostATe radIOtherapy usiNg the MRL acronym: DESTINATION overallStatus: RECRUITING date: 2024-02-29 date: 2025-04-01 date: 2027-04-01 date: 2024-02-28 date: 2024-03-05 name: The Netherlands Cancer Institute class: OTHER briefSummary: Trial design: A single centre phase II non-randomised study
|
Trial population: Men with intermediate risk localised prostate cancer
|
Recruitment target: 20 patients in total
|
Trial objectives:
|
* Primary To develop a 5 fraction de-escalated dose SBRT protocol capable of reducing side effects
|
* Secondary
|
* To assess levels of acute GU and GI toxicity (CTCAE)
|
* To assess levels of late GU and GI toxicity (CTCAE)
|
* To assess late sexual quality of life (expanded EPIC, IIEF-5)
|
* To assess biochemical relapse-free survival at 2 years
|
Trial treatment: All radiotherapy will be delivered on the MR-linac. Intraprostatic dose will be varied according to risk of local recurrence, based on mpMRI, PSA and histology. The whole prostate will receive 30 Gy in 5 fractions and the GTV plus intra-prostatic margin will receive an isotoxic 45 Gy prescription. conditions: Prostate Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: De-escalated radiotherapy measure: Technical feasibility of treating prostate cancer with toxicity minimising radiotherapy on a MR-linac measure: Acute GU toxicity measure: Acute GI toxicity measure: Late GU toxicity measure: Late GI toxicity measure: PROMs measure: Biochemical free survival sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Netherlands Cancer Institute status: RECRUITING city: Amsterdam zip: 1066CX country: Netherlands name: Floris Pos, MD PhD role: CONTACT phone: +31 20 512 9111 email: f.pos@nki.nl lat: 52.37403 lon: 4.88969 hasResults: False
|
<|newrecord|> nctId: NCT06284291 id: TMSpath id: RF-2021-12372804 type: OTHER_GRANT domain: Italian Ministry of Health briefTitle: Transcranial Magnetic Stimulation (TMS) in Genetic Epilepsies overallStatus: RECRUITING date: 2023-11-22 date: 2025-11-30 date: 2026-03-01 date: 2024-02-28 date: 2024-02-28 name: Meyer Children's Hospital IRCCS class: OTHER briefSummary: Transcranial magnetic stimulation (TMS) uses electromagnetic induction as an efficient, painless, non-invasive method to generate a suprathreshold current at the level of the encephalon, and provide in vivo measurements of cortical excitability and reactivity at the level of the motor cortex (TMS-EMG) or the entire cortical mantle (TMS-EEG). This study proposes TMS measurements as a diagnostic tool in patients to understand mechanisms of epileptogenesis related to genetic mutations, and prognostic to guide and monitor precision treatments. conditions: Epilepsy conditions: Genetic Disease studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: NONE count: 150 type: ESTIMATED name: transcranial magnetic stimulation (TMS) measure: Resting motor threshold measure: SICI measure: ICF measure: LICI measure: TEP amplitude measure: TEP latency sex: ALL minimumAge: 3 Years maximumAge: 70 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Meyer Children's Hospital IRCCS status: RECRUITING city: Firenze country: Italy name: Simona Balestrini, MD role: CONTACT email: simona.balestrini@meyer.it lat: 43.77925 lon: 11.24626 hasResults: False
|
<|newrecord|> nctId: NCT06284278 id: NCKU_PPGP_diaphragm briefTitle: Telehealth: Diaphragmatic vs. Pelvic Exercise in Postpartum Pregnancy-related Pelvic Girdle Pain overallStatus: RECRUITING date: 2023-10-20 date: 2024-05-31 date: 2024-07-31 date: 2024-02-28 date: 2024-02-28 name: YI-JU TSAI class: OTHER briefSummary: The goal of this interventional study is to compare investigate the short-term and long-term effects of 8-week real-time telehealth-based diaphragmatic breathing exercise and pelvic stabilization exercise on pain, disability, and quality of life in postpartum women with pregnancy-related pelvic girdle pain. conditions: Postpartum conditions: Pregnancy Related conditions: Pelvic Girdle Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 60 type: ESTIMATED name: Diaphragmatic breathing retraining name: Pelvic stabilization exercise name: pelvic anatomy education measure: Muscle function measures of lumbopelvic muscles measure: Diaphragm thickness measure: Diaphragm mobility measure: Diaphragm strength measure: Mechanical Property of Thoracolumbar Fascia measure: Functional performance of ASLR fatigue task measure: Functional performance of timed up and go test measure: Functional performance of 6m timed walk test measure: pain intensity measure of Numeric Rating Scale (NRS) measure: Disability Level: measure of pelvic girdle questionnaire(PGQ) measure: Health-related Quality of Life: Short Form-36 (SF36) measure: Fear Avoidance Belief: Tampa Scale of Kinesiophobia measure: Self-Efficacy: Pain Self-efficacy Questionnaire measure: Parenting Stress Level: Parenting Stress Index-Short Form (PSI-SF) measure: Self-perceived Change: Global Rating of Change Scale (GROC) sex: FEMALE minimumAge: 20 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Cheng Kung University status: RECRUITING city: Tainan zip: 701 country: Taiwan name: Tsai Yi-Ju role: CONTACT phone: 06-2353535 phoneExt: 5930 email: lulilutsai@gmail.com lat: 22.99083 lon: 120.21333 hasResults: False
|
<|newrecord|> nctId: NCT06284265 id: MMH-407-007 briefTitle: Clinical Trial of the Efficacy and Safety of Raphamin in Prevention of Recurrences of Chronic Bacterial Cystitis overallStatus: RECRUITING date: 2023-10-16 date: 2026-12-31 date: 2026-12-31 date: 2024-02-28 date: 2024-04-19 name: Materia Medica Holding class: INDUSTRY briefSummary: Clinical Trial of the Efficacy and Safety of Raphamin in Prevention of Recurrences of Chronic Bacterial Cystitis conditions: Cystitis Chronic conditions: Cystitis Bacterial conditions: Recurrence of Chronic Bacterial Cystitis studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 632 type: ESTIMATED name: Raphamin name: Placebo measure: Time to the first recurrence of chronic bacterial cystitis measure: Percentage of patients with a reduction of recurrences of chronic bacterial cystitis measure: Average duration of episodes of recurrences of chronic bacterial cystitis measure: Average number of recurrences of chronic bacterial cystitis measure: Severity of chronic bacterial cystitis recurrences measure: Change in the severity of chronic bacterial cystitis recurrences measure: VAS score at the end of the follow-up period measure: The Presence of Adverse Events (AEs). measure: Changes in Vital Signs (Blood Pressure measured in mm Hg) measure: Changes in Vital Signs (Pulse Rate (Heart Rate) measured in beats per minute) measure: Changes in Vital Signs (Respiration Rate (Breathing Rate) measured in breaths per minute) measure: Proportion of patients with clinically significant laboratory abnormalities sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Scientific Center for Family Health and Human Reproduction Problems/Reproductive Health Department status: RECRUITING city: Irkutsk zip: 664003 country: Russian Federation name: Larisa Suturina, Prof. role: CONTACT name: Larisa Suturina, Prof. role: PRINCIPAL_INVESTIGATOR lat: 52.29778 lon: 104.29639 facility: Kazan State Medical University/Professor's clinic status: NOT_YET_RECRUITING city: Kazan zip: 420012 country: Russian Federation name: Ruslan Fatykhov, MD, PhD role: CONTACT name: Ruslan Fatykhov, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 55.78874 lon: 49.12214 facility: LLC "Fenareta" Women's and Men's Health Clinic" status: RECRUITING city: Kemerovo zip: 650000 country: Russian Federation name: Natalia Artymuk, Prof. role: CONTACT name: Natalia Artymuk, Prof. role: PRINCIPAL_INVESTIGATOR lat: 55.33333 lon: 86.08333 facility: City Clinical Hospital #15 named after O.M. Filatov Department of Health of Moscow status: RECRUITING city: Moscow zip: 111539 country: Russian Federation name: Vladimir Kuzmin, Prof. role: CONTACT name: Vladimir Kuzmin, Prof. role: PRINCIPAL_INVESTIGATOR lat: 55.75222 lon: 37.61556 facility: City Clinical Hospital # 13/Gynecology Department # 1 status: RECRUITING city: Moscow zip: 115280 country: Russian Federation name: Felix Grigoryan, PhD role: CONTACT name: Felix Grigoryan, PhD role: PRINCIPAL_INVESTIGATOR lat: 55.75222 lon: 37.61556 facility: Clinical Hospital # 85 of the Federal Medical and Biological Agency/Central polyclinic status: RECRUITING city: Moscow zip: 115409 country: Russian Federation name: Sergey Levakov, Prof. role: CONTACT name: Sergey Levakov, Prof. role: PRINCIPAL_INVESTIGATOR lat: 55.75222 lon: 37.61556 facility: Research Institute of Rheumatology named after V.A. Nasonova status: RECRUITING city: Moscow zip: 115522 country: Russian Federation name: Victoria Gelashvili, MD role: CONTACT name: Victoria Gelashvili, MD role: PRINCIPAL_INVESTIGATOR lat: 55.75222 lon: 37.61556 facility: National Medical Research Center for Obstetrics, Gynecology and Perinatology named after V.I. Kulakov/Department of Aesthetic Gynecology and Rehabilitation status: RECRUITING city: Moscow zip: 117198 country: Russian Federation name: Inna Apolikhina, Prof. role: CONTACT name: Inna Apolikhina, Prof. role: PRINCIPAL_INVESTIGATOR lat: 55.75222 lon: 37.61556 facility: Peoples' Friendship University of Russia/Department of Obstetrics and Gynecology with a course in perinatology status: WITHDRAWN city: Moscow zip: 117198 country: Russian Federation lat: 55.75222 lon: 37.61556 facility: Russian National Research Medical University named after N.I. Pirogov/Department of Obstetrics and Gynecology, Faculty of Medicine status: RECRUITING city: Moscow zip: 117997 country: Russian Federation name: Yulia Dobrokhotova, Prof. role: CONTACT name: Yulia Dobrokhotova, Prof. role: PRINCIPAL_INVESTIGATOR lat: 55.75222 lon: 37.61556 facility: City Clinical Hospital # 1 named after. N.I. Pirogov of the Moscow City Health Department status: RECRUITING city: Moscow zip: 119049 country: Russian Federation name: Sergey Kotov, PhD, MD role: CONTACT name: Sergey Kotov, PhD, MD role: PRINCIPAL_INVESTIGATOR lat: 55.75222 lon: 37.61556 facility: United hospital with clinic of the Administration of the President of the Russian Federation status: NOT_YET_RECRUITING city: Moscow zip: 119285 country: Russian Federation name: Nikolay Keshishev, MD, PhD role: CONTACT name: Nikolay Keshishev, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 55.75222 lon: 37.61556 facility: City Clinical Hospital # 67 named after L.A. Vorokhobov status: NOT_YET_RECRUITING city: Moscow zip: 121423 country: Russian Federation name: Olga Perevozkina, MD, PhD role: CONTACT name: Olga Perevozkina, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 55.75222 lon: 37.61556 facility: JSC "MEDSI Group of Companies" status: WITHDRAWN city: Moscow zip: 123056 country: Russian Federation lat: 55.75222 lon: 37.61556 facility: Moscow State Medical and Dental University named after A.I. Evdokimov/Department of Urologya status: RECRUITING city: Moscow zip: 127473 country: Russian Federation name: Dmitry Pushkar, Prof. role: CONTACT name: Dmitry Pushkar, Prof. role: PRINCIPAL_INVESTIGATOR lat: 55.75222 lon: 37.61556 facility: Privolzhsky District Medical Center status: RECRUITING city: Nizhny Novgorod zip: 603001 country: Russian Federation name: Vagif Atduev, Prof. role: CONTACT name: Vagif Atduev Vagif, Prof. role: PRINCIPAL_INVESTIGATOR lat: 56.32867 lon: 44.00205 facility: National Medical Research Center for Radiology/Research Institute of Urology and Interventional Radiology named after. N.A. Lopatkin status: NOT_YET_RECRUITING city: Obninsk zip: 105425 country: Russian Federation name: Tatyana Perepanova, Prof. role: CONTACT name: Tatyana Perepanova, Prof. role: PRINCIPAL_INVESTIGATOR lat: 55.09681 lon: 36.61006 facility: City Clinical Hospital status: NOT_YET_RECRUITING city: Pyatigorsk zip: 357500 country: Russian Federation name: Alexander Bardin, MD role: CONTACT name: Alexander Bardin, MD role: PRINCIPAL_INVESTIGATOR lat: 44.04861 lon: 43.05944 facility: Clinical and Diagnostic Center "Health" in Rostov-on-Don status: RECRUITING city: Rostov-on-Don zip: 344011 country: Russian Federation name: Igor Aboyan, Prof. role: CONTACT name: Igor Aboyan, Prof. role: PRINCIPAL_INVESTIGATOR lat: 47.23135 lon: 39.72328 facility: Rostov State Medical University/Department of Urology and Human Reproductive Health with a course of pediatric urology-andrology status: RECRUITING city: Rostov-on-Don zip: 344022 country: Russian Federation name: Mikhail Kogan, Prof. role: CONTACT name: Mikhail Kogan, Prof. role: PRINCIPAL_INVESTIGATOR lat: 47.23135 lon: 39.72328 facility: Rostov Central District Hospital status: NOT_YET_RECRUITING city: Rostov zip: 152155 country: Russian Federation name: Ariz Gyulmamedov, MD role: CONTACT name: Ariz Gyulmamedov, MD role: PRINCIPAL_INVESTIGATOR lat: 57.1914 lon: 39.41394 facility: JSC "Polyclinic Complex" status: WITHDRAWN city: Saint Petersburg zip: 190013 country: Russian Federation lat: 59.93863 lon: 30.31413 facility: LLC "Medical Center Capital-Polis" status: NOT_YET_RECRUITING city: Saint Petersburg zip: 190013 country: Russian Federation name: Dmitry Gorelov, MD role: CONTACT name: Dmitry Gorelov, MD role: PRINCIPAL_INVESTIGATOR lat: 59.93863 lon: 30.31413 facility: LLC "BioTechService" status: RECRUITING city: Saint Petersburg zip: 190121 country: Russian Federation name: Alexander Parshin, PhD role: CONTACT name: Alexander Parshin, PhD role: PRINCIPAL_INVESTIGATOR lat: 59.93863 lon: 30.31413 facility: City clinic # 44 status: NOT_YET_RECRUITING city: Saint Petersburg zip: 192071 country: Russian Federation name: Farzali Farzaliev, MD role: CONTACT name: Farzali Farzaliev, MD role: PRINCIPAL_INVESTIGATOR lat: 59.93863 lon: 30.31413 facility: All-Russian Center for Emergency and Radiation Medicine named after A.M. Nikiforov/Urology department status: RECRUITING city: Saint Petersburg zip: 194044 country: Russian Federation name: Vladislav Grigoriev, PhD role: CONTACT name: Vladislav Grigoriev, PhD role: PRINCIPAL_INVESTIGATOR lat: 59.93863 lon: 30.31413 facility: St. Luke's Clinical Hospital status: RECRUITING city: Saint Petersburg zip: 194044 country: Russian Federation name: Orlov Igor, PhD role: CONTACT name: Orlov Igor, PhD role: PRINCIPAL_INVESTIGATOR lat: 59.93863 lon: 30.31413 facility: City Multidisciplinary Hospital # 2/Urology department status: WITHDRAWN city: Saint Petersburg zip: 194354 country: Russian Federation lat: 59.93863 lon: 30.31413 facility: Llc "Medical Clinic" status: RECRUITING city: Saint Petersburg zip: 194356 country: Russian Federation name: Maxim Bushara, MD role: CONTACT name: Maxim Bushara, MD role: PRINCIPAL_INVESTIGATOR lat: 59.93863 lon: 30.31413 facility: Medical and sanitary unit No. 70 - branch of the St. Petersburg State Unitary Enterprise of Passenger Road Transport status: RECRUITING city: Saint Petersburg zip: 195197 country: Russian Federation name: Vadim Zubarev, PhD, MD role: CONTACT name: Vadim Zubarev, PhD, MD role: PRINCIPAL_INVESTIGATOR lat: 59.93863 lon: 30.31413 facility: LLC "Research Center Eco-Safety" status: TERMINATED city: Saint Petersburg zip: 196143 country: Russian Federation lat: 59.93863 lon: 30.31413 facility: Jsc "Northwestern Center of Evidence-Based Medicine" status: WITHDRAWN city: Saint Petersburg zip: 196158 country: Russian Federation lat: 59.93863 lon: 30.31413 facility: City Hospital # 15 status: NOT_YET_RECRUITING city: Saint Petersburg zip: 198205 country: Russian Federation name: Konstantin Dunets, MD role: CONTACT name: Konstantin Dunets, MD role: PRINCIPAL_INVESTIGATOR lat: 59.93863 lon: 30.31413 facility: Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott/Department of Gynecology and Endocrinology status: RECRUITING city: Saint Petersburg zip: 199034 country: Russian Federation name: Maria Yarmolinskaya, Prof. role: CONTACT name: Maria Yarmolinskaya, Prof. role: PRINCIPAL_INVESTIGATOR lat: 59.93863 lon: 30.31413 facility: City Pokrovskaya Hospital/Department of Urology status: RECRUITING city: Saint Petersburg zip: 199106 country: Russian Federation name: Andrey Gorelov, Prof. role: CONTACT name: Andrey Gorelov, Prof. role: PRINCIPAL_INVESTIGATOR lat: 59.93863 lon: 30.31413 facility: Sertolovo City Hospital status: NOT_YET_RECRUITING city: Sertolovo zip: 188650 country: Russian Federation name: Alexander Shvets, MD role: CONTACT name: Alexander Shvets, MD role: PRINCIPAL_INVESTIGATOR lat: 60.1444 lon: 30.20165 facility: Siberian State Medical University/Faculty clinics of Siberian State Medical University status: NOT_YET_RECRUITING city: Tomsk zip: 634050 country: Russian Federation name: Victor Latypov, MD, PhD role: CONTACT name: Victor Latypov, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 56.49771 lon: 84.97437 facility: Bashkir State Medical University/Department of Obstetrics and Gynecology # 1 status: WITHDRAWN city: Ufa zip: 450008 country: Russian Federation lat: 54.74306 lon: 55.96779 facility: Voronezh State Medical University named after N.N. Burdenko/Department of Urology status: RECRUITING city: Voronezh zip: 394036 country: Russian Federation name: Andrey Kuzmenko, Prof. role: CONTACT name: Andrey Kuzmenko, Prof. role: PRINCIPAL_INVESTIGATOR lat: 51.67204 lon: 39.1843 facility: Vsevolozhsk Clinical Interdistrict Hospital/Center for Outpatient Surgery status: RECRUITING city: Vsevolozhsk zip: 188643 country: Russian Federation name: Nikolay Kanareikin, MD role: CONTACT name: Nikolay Kanareikin, MD role: PRINCIPAL_INVESTIGATOR lat: 60.01512 lon: 30.67314 facility: Yaroslavl State Medical University/Department of Urology and Nephrology status: NOT_YET_RECRUITING city: Yaroslavl zip: 150000 country: Russian Federation name: Igor Shormanov, Prof. role: CONTACT name: Igor Shormanov, Prof. role: PRINCIPAL_INVESTIGATOR lat: 57.62987 lon: 39.87368 facility: LLC "Clinic of Modern Medicine Dr. Bogorodskaya" status: NOT_YET_RECRUITING city: Yaroslavl zip: 150001 country: Russian Federation name: Andrey Soloviev, MD, PhD role: CONTACT name: Andrey Soloviev, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 57.62987 lon: 39.87368 facility: LLC "Medical Center for Diagnosis and Prevention Plus" status: RECRUITING city: Yaroslavl zip: 150040 country: Russian Federation name: Svetlana Isakova, MD role: CONTACT name: Svetlana Isakova, MD role: PRINCIPAL_INVESTIGATOR lat: 57.62987 lon: 39.87368 facility: Regional Clinical Hospital/Urology department status: RECRUITING city: Yaroslavl zip: 150062 country: Russian Federation name: Dmitry Komlev, PhD role: CONTACT name: Dmitry Komlev, PhD role: PRINCIPAL_INVESTIGATOR lat: 57.62987 lon: 39.87368 hasResults: False
|
<|newrecord|> nctId: NCT06284252 id: TÜBİTAK-323S135 briefTitle: Virtual Game Simulation on Nursing Students' Physical Examination Skills overallStatus: NOT_YET_RECRUITING date: 2024-09-15 date: 2025-01-15 date: 2025-02-15 date: 2024-02-28 date: 2024-02-28 name: Necmettin Erbakan University class: OTHER name: TÜBİTAK briefSummary: The project is unique in that it will use virtual game simulation, a new learning method, and it will address the physical examination skills of nursing students, an area that has not been researched before. In the project, a randomized controlled research design with a pretest-posttest control group will be used. The population will consist of 200 second-year students enrolled in the Physical Examination in Nursing course at Necmettin Erbakan University, Faculty of Nursing, Department of Nursing, in the 2024-2025 Fall Semester. 120 students from the population who meet the research inclusion criteria will be randomly assigned to control (n=60) and experimental (n=60) groups according to their general academic success score. In collecting data; Introductory characteristics form, skill checklist for physical examination of the heart, skill checklist for physical examination of the abdomen, skill checklist for physical examination of the respiratory system and an evaluation form for the effect of virtual game simulation on skill practice for physical examination will be used. In the project, three different virtual game simulations will be developed for physical examinations of the heart, abdomen and respiratory system. During the fall semester, theoretical and laboratory demonstration applications will be carried out by the project team. A pre-test will be administered to all students, and then virtual game simulations will be made available to students in the experimental group for three weeks. Then, the virtual games will be closed to the students and a post-test will be administered to the experimental and control group students. After the final test application, virtual game simulations will be made available to students in the control group. In pre- and post-test applications, students will practice physical examination skills on simulated patients at three different stations (heart, abdomen and respiratory system) and will be evaluated by the project team according to skill checklists. After the skill evaluations, the students in the experimental group will be given a form to evaluate the effect of the virtual game simulation for physical examination on skill practice and will be asked to fill it out. conditions: Simulation of Physical Illness studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Control group and intervention group primaryPurpose: OTHER masking: TRIPLE maskingDescription: Participant blinding: In order to ensure participant blinding, all students will register to the site where virtual game simulations will be hosted.
|
Statistics blinding: In order to blind the statistics expert, at the end of data collection, the website expert will share the collected data with the statistics expert as group A and B data. The statistician will perform statistical analyzes without knowing which group is the control and which group is the experiment.
|
Researcher blinding: In order to ensure researcher blinding, the expert who designed the web page for virtual game simulations selected the students who registered on the website, using the "A" and "B" codes, according to the list he received from the statistics expert, on the website with a random group as control and one group as experiment. will assign it to the site. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 120 type: ESTIMATED name: Virtual Gaming Simulation measure: Skill assessment for physical examination of the abdomen (Pretest) measure: Skill assessment for physical examination of the heart(Pretest) measure: Evaluation of physical examination skills of the respiratory system(Pretest) measure: Skill assessment for physical examination of the abdomen (Posttest) measure: Skill assessment for physical examination of the heart(Posttest) measure: Evaluation of physical examination skills of the respiratory system(Posttest) sex: ALL minimumAge: 19 Years maximumAge: 25 Years stdAges: ADULT hasResults: False
|
<|newrecord|> nctId: NCT06284239 id: Tell Me Game briefTitle: Using Games in Teaching Nursing History overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-05 date: 2024-06 date: 2024-02-28 date: 2024-03-21 name: Necmettin Erbakan University class: OTHER briefSummary: Innovative learning methods can be used in teaching nursing history. One of the most preferred among these methods is learning through games. It is known that today's Generation Z students prefer active learning methods and want to learn by having fun instead of learning by rote. It is reported that learning through games improves students' knowledge and skills and increases retention. One of the methods of learning through games is the "tell me" game. The "Tell Me" game involves the narrator explaining the words prepared specifically for the subject to a group of students without using prohibited words. Other students in the group try to know the word explained. Thus, both the student narrator and the student trying to know actively use their critical thinking and decision-making skills. This research aims to determine the effect of the tell-all game used in teaching nursing history on students' learning and opinions. conditions: Education Nursing studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: It refers to the intervention group in which the "Tell Me" game will be played. primaryPurpose: OTHER masking: DOUBLE maskingDescription: Participants will be informed about the research. However, participants will not know which group they belong to. At the same time, the statistical analysis of the research will be carried out by an independent statistician. Thus, blinding of both the participant and the outcome assessor will be ensured. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 66 type: ESTIMATED name: Tell me about the game. measure: Nursing History Knowledge Test measure: Nursing History Teaching Evaluation Form sex: ALL minimumAge: 20 Years maximumAge: 24 Years stdAges: ADULT hasResults: False
|
<|newrecord|> nctId: NCT06284226 id: CCT-ANK-11 briefTitle: An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients acronym: CCT-ANK-11 overallStatus: WITHDRAWN date: 2022-03-25 date: 2025-06-30 date: 2025-12-31 date: 2024-02-28 date: 2024-04-16 name: Beijing Kejing Biotechnology Co., Ltd. class: INDUSTRY briefSummary: An exploratory clinical study to evaluate the safety and efficacy of NK cells (combined with standard therapy) in the treatment of solid tumor patients conditions: Solid Tumors (Pancreatic Cancer, Esophageal Cancer, Gastric Cancer, Cholangiocarcinoma, Lung Cancer and Ovarian Cancer) studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 0 type: ACTUAL name: Allogeneic NK（CCT-ANK-11) measure: To evaluate the safety and the efficacy sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06284213 id: 5U24NS100591 type: NIH link: https://reporter.nih.gov/quickSearch/5U24NS100591 briefTitle: Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium acronym: MarkVCID overallStatus: RECRUITING date: 2021-09-29 date: 2027-07 date: 2027-07 date: 2024-02-28 date: 2024-02-28 name: Massachusetts General Hospital class: OTHER name: Duke University name: Johns Hopkins University name: University of New Mexico name: University of Southern California name: University of Kentucky name: Rush University Medical Center name: University of Maryland, Baltimore name: University of California, San Francisco name: University of California, Los Angeles name: University of California, Davis name: University of Texas name: The University of Texas Health Science Center at San Antonio name: The University of Texas Health Science Center, Houston name: Mayo Clinic name: University of Mississippi Medical Center name: Washington University School of Medicine name: Olive View-UCLA Education & Research Institute briefSummary: Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia (MarkVCID) is an NIH-funded consortium dedicated to finding biomarkers involved in age-related thinking and memory problems. Alzheimer's disease and other dementias leave signatures on brain scans or in the blood called biomarkers. The MarkVCID study will measure a panel of candidate biomarkers in 1800 participants and watch them closely to see what they tell us about changes in brain function and risk of memory loss.
|
Age-related problems in thinking and memory represent some of the greatest risks to public health in the US and globally. Diseases that affect small blood vessels in the brain have been shown to be major contributors to these changes. However, research and patient care can be held back by limited biomarkers that identify who should be treated.
|
The MarkVCID Consortium includes 17 US medical centers, a Coordinating Center, an External Advisory Committee, and NIH leadership. Data and biospecimens collected as part of this research study will be stored in a research database and biorepositories, so that researchers can use this information to study brain function. conditions: Cognitive Impairment conditions: Dementia studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 1800 type: ESTIMATED name: No interventions measure: SVD progression as measured by decline in global cognition measure: SVD progression as measured by decline in executive function sex: ALL minimumAge: 60 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Southern California status: RECRUITING city: Los Angeles state: California zip: 90033 country: United States name: Danny JJ Wang, PhD, MSCE role: CONTACT phone: 323-442-7246 email: JJ.Wang@loni.usc.edu lat: 34.05223 lon: -118.24368 facility: University of California Los Angeles status: RECRUITING city: Los Angeles state: California zip: 90095 country: United States name: Jason Hinman, MD, PhD role: CONTACT phone: 310-794-1195 email: JHinman@mednet.ucla.edu lat: 34.05223 lon: -118.24368 facility: University of California Davis status: RECRUITING city: Sacramento state: California zip: 95817 country: United States name: Pauline Maillard, PhD role: CONTACT phone: 916-734-3588 email: pmaillard@ucdavis.edu lat: 38.58157 lon: -121.4944 facility: University of California San Francisco status: RECRUITING city: San Francisco state: California zip: 94158 country: United States name: Joel Kramer, PsyD role: CONTACT phone: 415-476-5572 email: Joel.Kramer@ucsf.edu lat: 37.77493 lon: -122.41942 facility: Olive View - UCLA Medical Center status: RECRUITING city: Sylmar state: California zip: 91342 country: United States name: Keith Vossel, MD role: CONTACT phone: 310-794-1195 email: KVossel@mednet.ucla.edu lat: 34.30778 lon: -118.44925 facility: Mayo Clinic Florida status: RECRUITING city: Jacksonville state: Florida zip: 32224 country: United States name: Gregory Day role: CONTACT phone: 904-953-0856 email: Day.Gregory@mayo.edu lat: 30.33218 lon: -81.65565 facility: Rush University Medical Center & Illinois Institute of Technology status: RECRUITING city: Chicago state: Illinois zip: 60612 country: United States name: Konstantinos Arfanakis, PhD role: CONTACT phone: 312-567-3864 email: Konstantinos_Arfanakis@rush.edu lat: 41.85003 lon: -87.65005 facility: University of Kentucky status: RECRUITING city: Lexington state: Kentucky zip: 40536 country: United States name: Gregory Jicha, MD, PhD role: CONTACT phone: 859-257-1000 email: gregory.jicha@uky.edu lat: 37.98869 lon: -84.47772 facility: University of Maryland, Baltimore status: RECRUITING city: Baltimore state: Maryland zip: 21201 country: United States name: Peiying Liu, PhD role: CONTACT phone: 410-706-2441 email: PeiyingLiu@som.umaryland.edu lat: 39.29038 lon: -76.61219 facility: Johns Hopkins University status: RECRUITING city: Baltimore state: Maryland zip: 21287 country: United States name: Hanzhang Lu, PhD role: CONTACT phone: 410-955-1431 email: hlu3@jhmi.edu lat: 39.29038 lon: -76.61219 facility: Mayo Clinic Rochester status: RECRUITING city: Rochester state: Minnesota zip: 55901 country: United States name: Ronald Petersen, MD, PhD role: CONTACT phone: 507-284-1588 email: peter8@mayo.edu lat: 44.02163 lon: -92.4699 facility: University of Mississippi Medical Center status: RECRUITING city: Jackson state: Mississippi zip: 39216 country: United States name: Gwen Windham, MD role: CONTACT phone: 601-984-5610 email: gwindham@umc.edu lat: 32.29876 lon: -90.18481 facility: Washington University in St. Louis status: RECRUITING city: Saint Louis state: Missouri zip: 63110 country: United States name: Jin-Moo Lee, MD, PhD role: CONTACT phone: 314-362-7382 email: leejm@wustl.edu lat: 38.62727 lon: -90.19789 facility: University of New Mexico status: RECRUITING city: Albuquerque state: New Mexico zip: 87131 country: United States name: Gary Rosenberg, MD role: CONTACT phone: 505-272-3315 email: GRosenberg@salud.unm.edu lat: 35.08449 lon: -106.65114 facility: University of Texas Southwestern status: RECRUITING city: Dallas state: Texas zip: 75390 country: United States name: Rong Zhang, PhD role: CONTACT phone: 214-345-4619 email: RongZhang@texashealth.org lat: 32.78306 lon: -96.80667 facility: University of Texas Health Science Center Houston status: RECRUITING city: Houston state: Texas zip: 77030 country: United States name: Sean Savitz, MD role: CONTACT phone: 713-500-7083 email: Sean.I.Savitz@uth.tmc.edu lat: 29.76328 lon: -95.36327 facility: University of Texas Health Science Center San Antonio status: RECRUITING city: San Antonio state: Texas zip: 78229 country: United States name: Claudia Satizabal, PhD role: CONTACT phone: 210-450-8417 email: satizabal@uthscsa.edu lat: 29.42412 lon: -98.49363 hasResults: False
|
<|newrecord|> nctId: NCT06284200 id: sarcopenia eRA briefTitle: Presence and Comparison of Sarcopenia in Early Rheumatoid Arthritis and Rheumatoid Arthritis overallStatus: RECRUITING date: 2023-06-23 date: 2024-03-23 date: 2024-06-23 date: 2024-02-28 date: 2024-02-28 name: Kayseri City Hospital class: OTHER_GOV briefSummary: introduction: In this study, the presence of sarcopenia in cases with early rheumatoid arthritis and established rheumatoid arthritis will be compared.
|
Materials and Method: According to the power analysis, 24 patients with early rheumatoid arthritis and 24 patients with established rheumatoid arthritis who meet the 2010 American College of Rheumatology (ACR) / European Alliance of Associations for Rheumatology (EULAR) rheumatoid arthritis (RA) classification criteria will be included in the study. conditions: Sarcopenia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 48 type: ESTIMATED measure: Evaluation of Muscle Mass measure: Evaluation of Muscle Strength measure: Evaluation of Muscle Performance measure: Rheumatoid Arthritis Quality of Life Scale measure: Health Assessment Questionnaire (HAQ) measure: Hospital Anxiety and Depression Scale (HADS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Health Sciences University, Kayseri Medicine Faculty status: RECRUITING city: Kocasinan state: Kayseri zip: 38125 country: Turkey name: MEHMET KÖKSAL, M.D. role: CONTACT phone: +905514043114 email: dr.mhmtkksl@gmail.com hasResults: False
|
<|newrecord|> nctId: NCT06284187 id: KhonKaenH briefTitle: Diagnosis Test of Real-time Polymerase Chain Reaction (RT-PCR) for Pulmonary Tuberculosis overallStatus: COMPLETED date: 2023-01-01 date: 2023-10-31 date: 2023-12-31 date: 2024-02-28 date: 2024-02-28 name: Khon Kaen Hospital class: OTHER_GOV briefSummary: BACKGROUND: Pulmonary tuberculosis remains the leading cause of morbidity and mortality in Thailand. The microbiological detection of TB is important because of early and correct diagnosis, drug resistance testing and ensures that the effective treatment can be achieved and in a timely manner. Mycobacterial culture is the gold standard diagnostic test. Currently, a real-time polymerase chain reaction (RT-PCR) assay, such as Allplex™ MTB/MDRe Detection, Seegene is commonly used.
|
OBJECTIVE: To evaluate the diagnosis value of the real-time multiplex PCR by using Allplex™ MTB/MDRe Detection kit to detect MTB from sputum specimens with a gold standard TB culture. conditions: Tuberculosis conditions: Pulmonary studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: RETROSPECTIVE count: 120 type: ACTUAL measure: Number of participants with pulmonary TB by Allplex™ MTB/MDRe sex: ALL minimumAge: 15 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Thananit Sangkomkamhang city: Khon Kaen zip: 40000 country: Thailand lat: 16.44671 lon: 102.833 hasResults: False
|
<|newrecord|> nctId: NCT06284174 id: B-BR-109-054-T briefTitle: Effectiveness of Povidone-Iodine Versus Chlorhexidine Gluconate Solutions in Reducing Microbial Contamination in Spinal Surgery Wounds During Intraoperative Soaking. overallStatus: RECRUITING date: 2021-01-01 date: 2024-12-31 date: 2024-12-31 date: 2024-02-28 date: 2024-02-28 name: National Cheng-Kung University Hospital class: OTHER briefSummary: This study aims to assess the efficacy of intraoperative wound irrigation with iodine-containing and chlorhexidine-containing solutions in reducing bacterial colonization during spine surgery, and to determine which solution is more effective. Additionally, we aim to evaluate any side effects associated with the use of these two antiseptic solutions for wound irrigation. conditions: Spine Infection studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This research will include patients diagnosed with lumbar spinal stenosis causing nerve compression, who are scheduled for open spinal decompression and fusion surgery. Patients will be randomly assigned to one of three groups: a control group (soaked with 0.9% normal saline), an iodine group (soaked with 3.5% povidone-iodine solution), and a CHG group (soaked with 0.05% chlorhexidine gluconate). All groups will receive the same surgical pre-care, preoperative disinfection, and prophylactic antibiotics. Before wound closure, each group will undergo different irrigation solutions for soaking the wound for three minutes followed by rinsing with copious saline. Samples from deep and superficial tissues and implants will be taken for bacterial culture and molecular biochip analysis. primaryPurpose: PREVENTION masking: DOUBLE maskingDescription: Patients will be randomly assigned by computer to one of three groups: a control group (soaked with 0.9% normal saline), an iodine group (soaked with 3.5% povidone-iodine solution), and a CHG group (soaked with 0.05% chlorhexidine gluconate). All groups will receive the same surgical pre-care, preoperative disinfection, and prophylactic antibiotics.
|
All patients understood the experimental process and signed the consent form. The patients did not know the group they were assigned to during the whole process. The bacterial culturers, examiners and clinical outcome assessors did not know the patient group. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 105 type: ESTIMATED name: Povidone-iodine solution; chlorhexidine gluconate measure: Bacteria culture and Polymerase chain reaction exam measure: Post operative infection sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Cheng Kung University Hospital status: RECRUITING city: Tainan zip: 704 country: Taiwan name: Wei-Ren Su, M.D., M.Sc. role: CONTACT phone: 886-6-2766689 email: suwr@ms28.hinet.net lat: 22.99083 lon: 120.21333 hasResults: False
|
<|newrecord|> nctId: NCT06284161 id: RBHP 2020 GUY id: 2020-A02765-34 type: OTHER domain: ANSM briefTitle: QCT in ALS Diagnosis, Mechanistic Understanding and Follow-up acronym: PEM-SLA overallStatus: RECRUITING date: 2022-06-28 date: 2025-06-28 date: 2026-02-28 date: 2024-02-28 date: 2024-02-28 name: University Hospital, Clermont-Ferrand class: OTHER briefSummary: Multidisciplinary management of amyotrophic lateral sclerosis (ALS) can significantly increase survival but also improve the quality of life of patients. The evaluation of cortical-spinal motor neuron damage is currently based only on the assessment of clinical data. However, the alteration of the central motor pathway and conduction can be identified and quantified by different techniques using motor-evoked potentials (MEP). The combined quadriceps test (QCT) has been developed to assess central and peripheral motor pathway conduction. This test allows to quantify central and peripheral part of a mixed disorder, and to detect physiological hyporeflexia or hyperreflexia which, in the case of suspected ALS, can lead to interpretation problems.
|
The evolution of the QCT parameters during the course of pathology will lead to determine the preponderance of an initial central involvement, but also its extension throughout the pathology. The study of these parameters as well as the clinical course of the disease could reveal a correlation between peripheral and central involvement. This link would provide arguments in favor of pathophysiological hypotheses of disease onset and progression. From a prognostic point of view and depending on the quantification of central and peripheral involvement, the QCT would make it possible to characterize the different ALS phenotypes. This phenotypic characterization would help identify prognostic factors at diagnosis.
|
The investigators propose a cohort study with the exploration of central motor neuron damage by QCT during the course of ALS in order to provide arguments for a better mechanistic understanding and follow-up of this disease with a poor prognosis. conditions: Amyotrophic Lateral Sclerosis studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 30 type: ESTIMATED name: Quadriceps Combined Test measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Parameters from the QCT (Quadriceps Combined Test) measure: Clinical and paraclinical likely course data measure: Clinical and paraclinical likely course data measure: Clinical and paraclinical likely course data measure: Clinical and paraclinical likely course data measure: Clinical and paraclinical likely course data measure: Clinical and paraclinical likely course data measure: Clinical and paraclinical likely course data measure: Clinical and paraclinical likely course data measure: Clinical and paraclinical likely course data measure: Clinical and paraclinical likely course data measure: Clinical and paraclinical likely course data measure: Clinical and paraclinical likely course data measure: Clinical and paraclinical likely course data measure: Clinical and paraclinical likely course data measure: Clinical and paraclinical likely course data measure: Clinical and paraclinical likely course data measure: Clinical and paraclinical likely course data measure: Clinical and paraclinical likely course data measure: Clinical and paraclinical likely course data measure: Clinical and paraclinical likely course data measure: Clinical and paraclinical likely course data measure: Clinical and paraclinical likely course data sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHU de Clermont-Ferrand status: RECRUITING city: Clermont-Ferrand zip: 63000 country: France name: Lise Laclautre role: CONTACT phone: +33473754963 email: promo_interne_drci@chu-clermontferrand.fr name: Nathalie Guy role: PRINCIPAL_INVESTIGATOR lat: 45.77966 lon: 3.08628 hasResults: False
|
<|newrecord|> nctId: NCT06284148 id: Pro00093964 id: 5R18HS025654-03 type: AHRQ link: https://reporter.nih.gov/quickSearch/5R18HS025654-03 briefTitle: Confidential IPV Screening Tool overallStatus: COMPLETED date: 2010-10-06 date: 2023-07-31 date: 2023-07-31 date: 2024-02-28 date: 2024-02-28 name: Medical University of South Carolina class: OTHER name: Agency for Healthcare Research and Quality (AHRQ) briefSummary: Intimate partner violence (IPV) against women in the US is a serious public health problem and a human rights issue. Our research team has developed confidential screening tools using exam-room computer for intimate partner violence to be used in primary care. conditions: Violence, Domestic studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: This is a stepped wedge cluster randomized trial which has 3 sequences starting intervention in randomized order. primaryPurpose: SCREENING masking: NONE count: 19655 type: ACTUAL name: Screening for intimate partner violence name: Assessment and referral measure: IPV positive (Yes/No) measure: Screening completed (Yes/No) measure: Severity of risk measure: Physician compliance with IPV management tools sex: ALL minimumAge: 18 Years maximumAge: 49 Years stdAges: ADULT facility: Biomedical Informatics Center city: Charleston state: South Carolina zip: 29403 country: United States lat: 32.77657 lon: -79.93092 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-12-01 uploadDate: 2024-02-20T12:06 filename: Prot_SAP_000.pdf size: 179261 hasResults: False
|
<|newrecord|> nctId: NCT06284135 id: 2017-PS-03 id: PV6099 type: OTHER domain: Martini-Klinik briefTitle: MICHL-trial: Impact of Peritoneal Bladder Flap in RARP Patients on Lymphoceles overallStatus: COMPLETED date: 2017-06-19 date: 2019-10-16 date: 2021-05-31 date: 2024-02-28 date: 2024-02-28 name: Martini-Klinik am UKE GmbH class: OTHER briefSummary: A two-armed prospective randomised, controlled, single-centre trial on 1080 patients with prostate cancer who underwent robot-assisted radical prostatectomy with bilateral pelvic lymph node dissection was carried out. Patients in the intervention arm received fixation of the peritoneal flap of the bladder to the plexus Santorini at the end of surgery (Michl-technique, MT); in the control group, surgery was performed without this modification. The primary endpoint was the rate of lymphoceles requiring intervention. conditions: Lymphocele After Surgical Procedure studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE whoMasked: PARTICIPANT count: 1080 type: ACTUAL name: Michl-stitch measure: rate of lymphoceles requiring intervention after RARP measure: total lymphocele rate after RARP measure: other complications ≥ grade IIIa according to Clavien-Dindo after RARP measure: continence rates after RARP sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Martini-Klinik am UKE GmbH city: Hamburg zip: 20246 country: Germany lat: 53.57532 lon: 10.01534 hasResults: False
|
<|newrecord|> nctId: NCT06284122 id: MorningLyte briefTitle: Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 acronym: MorningLyte overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2028-11 date: 2034-04 date: 2024-02-28 date: 2024-03-15 name: The Lymphoma Academic Research Organisation class: OTHER name: Lymphoma Study Association name: Swiss Group for Clinical Cancer Research name: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea briefSummary: This study is a phase III, randomized, open-label, international, multicenter, interventional trial, designed to compare the efficacy and safety of mosunetuzumab in combination with lenalidomide versus anti-CD20 monoclonal antibody (mAb) plus chemotherapy in patients with previously untreated FLIPI 2-5 follicular lymphoma. conditions: Follicular Lymphoma studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 790 type: ESTIMATED name: Mosunetuzumab name: Lenalidomide name: Rituximab name: Obinutuzumab name: Cyclophosphamide name: Doxorubicin name: Vincristin name: Prednisone name: Rituximab name: Obinutuzumab name: Bendamustin measure: Progression Free Survival (PFS) measure: Progression Free Survival (PFS) measure: Overall Response (OR) measure: Complete Metabolic Rate (CMR) measure: Overall Response (OR) measure: Complete Metabolic Rate (CMR) measure: Best Overall Response (CMR + PMR) rate measure: Best Overall Response (CMR + PMR) rate measure: Progression of disease within 2 years (POD24) measure: PFS measure: PFS measure: Event Free Survival (EFS) by Lugano 2014 measure: Event Free Survival (EFS) by Lugano 2014 measure: Time to Next Anti-Lymphoma Treatment (TTNLT) measure: Time to Next Anti-Lymphoma Treatment (TTNLT) measure: Duration of response measure: Duration of response measure: Overall Response (OR) measure: Complete Metabolic Rate (CMR) measure: Duration of complete response measure: Duration of complete response measure: Overall Survival (OS) measure: Overall Survival (OS) measure: Incidence and severity of Adverse Events (AE) including Serious and Special Interest AE (SAEs and AESIs) measure: Incidence and severity of AEs including SAEs and AESIs measure: Tolerability, as assessed by incidence of dose interruptions, delays, dose reductions, and study treatment discontinuation measure: Tolerability, as assessed by incidence of dose interruptions, delays, dose reductions, and study treatment discontinuation measure: Incidence of Second Primary Malignancies (SPM) measure: Incidence of Second Primary Malignancies (SPM) measure: anti-drug antibodies (ADA) to mosunetuzumab measure: Time to deterioration in physical functioning measure: Time to deterioration in lymphoma symptoms measure: Maximum serum concentration of mosunetuzumab - Cmax measure: Minimum serum concentration of mosunetuzumab - Cmin measure: Area under the curve of serum concentration of mosunetuzumab - AUC measure: Maximum serum concentration of lenalidomide - Cmax measure: Minimum serum concentration of lenalidomide - Cmin measure: Area under the curve of serum concentration of lenalidomide - AUC sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: AZ SINT-JAN BRUGGE - OOSTENDE AV - Service Hématologie city: Brugge zip: 8000 country: Belgium name: Sylvia SNAUWAERT, Pr role: CONTACT lat: 51.20892 lon: 3.22424 facility: INSTITUT JULES BORDET - Service Hématologie city: Bruxelles zip: 1070 country: Belgium name: Marie MAEREVOET, MD role: CONTACT lat: 50.85045 lon: 4.34878 facility: UNIVERSITE CATHOLIQUE DE LOUVAIN SAINT-LUC - Service Hématologie city: Bruxelles zip: 1200 country: Belgium name: Eric VAN DEN NESTE, Pr role: CONTACT lat: 50.85045 lon: 4.34878 facility: GRAND HOPITAL DE CHARLEROI - Service Hématologie city: Charleroi zip: 6000 country: Belgium name: Delphine PRANGER, MD role: CONTACT lat: 50.41136 lon: 4.44448 facility: UNIVERSITAIR ZIEKENHUIS GENT - Service Hématologie city: Gent zip: 9000 country: Belgium name: Ciel DE WRIENDT, MD role: CONTACT lat: 51.05 lon: 3.71667 facility: CHU DE LIEGE - Service Hématologie city: Liège zip: 4000 country: Belgium name: Christophe BONNET, Pr role: CONTACT lat: 50.63373 lon: 5.56749 facility: CHR VERVIERS - LA TOURELLE - Service Hématologie city: Verviers zip: 4800 country: Belgium name: Gaetan VANSTRAELEN, MD role: CONTACT lat: 50.58907 lon: 5.86241 facility: CHU UCL NAMUR - SITE GODINNE - Service Hématologie city: Yvoir zip: 5530 country: Belgium name: Gilles CROCHET, MD role: CONTACT lat: 50.3279 lon: 4.88059 facility: CH d'AVIGNON - HOPITAL HENRI DUFFAUT - Service d'Onco-Hématologie city: Avignon zip: 84000 country: France name: Hacène ZERAZHI, MD role: CONTACT lat: 43.94834 lon: 4.80892 facility: CH DE LA COTE BASQUE - Service Hématologie city: Bayonne zip: 64100 country: France name: Sophie BERNARD, MD role: CONTACT lat: 43.48333 lon: -1.48333 facility: CHU JEAN MINJOZ - Service Hématologie city: Besançon zip: 25030 country: France name: Adrien CHAUCHET, MD role: CONTACT lat: 47.24878 lon: 6.01815 facility: INSTITUT BERGONIE - Service d'Oncologie Médicale city: Bordeaux zip: 33076 country: France name: Fontanet BIJOU, MD role: CONTACT lat: 44.84044 lon: -0.5805 facility: CENTRE HOSPITALIER JEAN ROUGIER - Service d'Oncologie - Hématologie city: Cahors zip: 46005 country: France name: Martin GAUTHIER, MD role: CONTACT lat: 44.4491 lon: 1.43663 facility: CH METROPOLE SAVOIE - SITE CHAMBERY - Service Hématologie city: Chambéry zip: 73011 country: France name: Arthur DONY, MD role: CONTACT lat: 45.56667 lon: 5.93333 facility: CHU ESTAING - Service Thérapie Cellulaire et Hématologie Clinique city: Clermont-Ferrand zip: 63003 country: France name: Romain GUIEZE, Pr role: CONTACT lat: 45.77966 lon: 3.08628 facility: HOPITAL HENRI MONDOR - Unité Hémopathies Lymphoïdes city: Créteil zip: 94010 country: France name: François LEMONNIER, MD role: CONTACT lat: 48.78333 lon: 2.46667 facility: CHU DIJON BOURGOGNE - Service Hématologie Clinique city: Dijon zip: 21000 country: France name: Amandine DURAND, MD role: CONTACT lat: 47.31667 lon: 5.01667 facility: CHD DE VENDEE - Service Hématologie city: La Roche-sur-Yon zip: 85925 country: France name: Nadine MORINEAU, MD role: CONTACT lat: 46.66667 lon: -1.43333 facility: CHU DE GRENOBLE - Service Hématologie city: La Tronche zip: 38700 country: France name: Sylvain CARRAS, MD role: CONTACT lat: 45.20429 lon: 5.73645 facility: HOPITAL SAINT VINCENT-DE-PAUL - Service Hématologie city: Lille zip: 59020 country: France name: Sandy AMORIM, MD role: CONTACT lat: 50.63297 lon: 3.05858 facility: CHRU DE LILLE - HOPITAL CLAUDE HURIEZ - Service Hématologie city: Lille zip: 59037 country: France name: Franck MORSCHHAUSER, Pr role: CONTACT lat: 50.63297 lon: 3.05858 facility: CHU DE LIMOGES - HOPITAL DUPUYTREN - Service Hématologie Clinique et Thérapie Cellulaire city: Limoges zip: 87042 country: France name: Julie ABRAHAM, MD role: CONTACT lat: 45.83153 lon: 1.25781 facility: INSTITUT PAOLI CALMETTES - Service Hématologie city: Marseille zip: 13273 country: France name: Gabriel BRISOU, MD role: CONTACT lat: 43.29551 lon: 5.38958 facility: CHU DE MONTPELLIER - Département d'Hématologie Clinique city: Montpellier zip: 34090 country: France name: Guillaume CARTRON, Pr role: CONTACT lat: 43.61092 lon: 3.87723 facility: GH REGION MULHOUSE ET SUD ALSACE - HOPITAL EMILE MULLER - Service Hématologie city: Mulhouse zip: 68100 country: France name: Bernard DRENOU, MD role: CONTACT lat: 47.75 lon: 7.33333 facility: CHU DE NANTES - Service Hématologie city: Nantes zip: 44093 country: France name: Thomas GASTINNE, MD role: CONTACT lat: 47.21725 lon: -1.55336 facility: CENTRE HOSPITALIER DE NIORT - Médecine interne city: Niort zip: 79021 country: France name: Gaëlle OLIVIER, MD role: CONTACT lat: 46.32313 lon: -0.45877 facility: HOPITAL SAINT-LOUIS - Service Hématologie city: Paris zip: 75475 country: France name: Catherine THIEBLEMONT, Pr role: CONTACT lat: 48.85341 lon: 2.3488 facility: CHU DE BORDEAUX - HOPITAL HAUT-LEVEQUE - CENTRE FRANCOIS MAGENDIE - Service d'Hématologie et Thérapie Cellulaire city: Pessac zip: 33604 country: France name: François-Xavier GROS, MD role: CONTACT lat: 44.81011 lon: -0.64129 facility: CHU LYON-SUD - Hématologie city: Pierre-Bénite zip: 69495 country: France lat: 45.7009 lon: 4.82511 facility: CHI POISSY SAINT-GERMAIN-EN-LAYE - Service Hématologie city: Poissy zip: 78303 country: France name: Mohammed BOUDERBALA, MD role: CONTACT lat: 48.92902 lon: 2.04952 facility: CHU DE POITIERS - HOPITAL DE LA MILETRIE - Service d'Oncologie Hématologique et Thérapie Cellulaire city: Poitiers zip: 86021 country: France name: Stéphanie GUIDEZ, MD role: CONTACT lat: 46.58333 lon: 0.33333 facility: CH ANNECY GENEVOIS - SITE D'ANNECY - Service Hématologie city: Pringy zip: 74374 country: France name: Hannah MOATTI, MD role: CONTACT lat: 45.94622 lon: 6.12608 facility: CHU DE REIMS - HOPITAL ROBERT DEBRE - Service Hématologie city: Reims zip: 57092 country: France name: Eric DUROT, MD role: CONTACT lat: 49.25 lon: 4.03333 facility: CHU PONTCHAILLOU - Hématologie Clinique city: Rennes zip: 35033 country: France name: Roch HOUOT, Pr role: CONTACT lat: 48.11198 lon: -1.67429 facility: CENTRE HENRI BECQUEREL - Service Hématologie city: Rouen zip: 76038 country: France lat: 49.44313 lon: 1.09932 facility: INSTITUT CURIE - SITE SAINT-CLOUD - Service Hématologie city: Saint-Cloud zip: 92210 country: France name: Clémentine SARKOZY, MD role: CONTACT lat: 48.84598 lon: 2.20289 facility: Institut de Cancérologie et d'Hématologie Universitaire de Saint-Étienne - Service Hématologie city: Saint-Priest-en-Jarez zip: 42270 country: France name: Ludovic FOUILLET, MD role: CONTACT lat: 45.47501 lon: 4.37614 facility: INSTITUT DE CANCEROLOGIE STRASBOURG EUROPE - Unité de Recherche Clinique city: Strasbourg zip: 67033 country: France name: Luc-Matthieu FORNECKER, Pr role: CONTACT lat: 48.58392 lon: 7.74553 facility: IUCT ONCOPOLE - Service Hématologie city: Toulouse zip: 31059 country: France name: Loïc YSEBAERT, MD role: CONTACT lat: 43.60426 lon: 1.44367 facility: CHU BRETONNEAU - Service Cancérologie - Hématologie et Thérapie Cellulaire city: Tours zip: 37044 country: France name: Laurianne DRIEU LA ROCHELLE, MD role: CONTACT lat: 47.38333 lon: 0.68333 facility: CH DE VALENCIENNES - HOPITAL JEAN BERNARD - Service Hématologie city: Valenciennes zip: 59322 country: France name: Sabine TRICOT, MD role: CONTACT lat: 50.35 lon: 3.53333 facility: CHU BRABOIS - Service Hématologie city: Vandœuvre-lès-Nancy zip: 54511 country: France name: Pierre FEUGIER, Pr role: CONTACT lat: 48.65 lon: 6.18333 facility: CH DE BRETAGNE ATLANTIQUE - HOPITAL CHUBERT - Service Hématologie city: Vannes zip: 56017 country: France name: Antoine BONNET, MD role: CONTACT lat: 47.66667 lon: -2.75 facility: GUSTAVE ROUSSY CANCER CAMPUS GRAND PARIS - Département Médecine Oncologique city: Villejuif zip: 94085 country: France name: Vincent RIBRAG, MD role: CONTACT lat: 48.7939 lon: 2.35992 facility: UNIVERSITATSKLINIKUM REGENSBURG - Klinik für Innere Medizin III city: Regensburg zip: 93053 country: Germany name: Stephanie MAYER, MD role: CONTACT lat: 49.01513 lon: 12.10161 facility: UNIV KLINIKUM ULM - INNERE MEDIZIN III - Service Hématologie city: Ulm zip: 89081 country: Germany name: Christian BUSKE, Pr role: CONTACT lat: 48.39841 lon: 9.99155 facility: INSTITUTO PORTUGUES DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL - Departamento Hematologia city: Lisboa zip: 1099 country: Portugal name: Maria GOMES DA SILVA, Pr role: CONTACT lat: 38.71667 lon: -9.13333 facility: HOSPITAL CLINICO SALAMANCA - Servicio de Hematologia city: Salamanca zip: 37007 country: Spain name: Alejandro MARTIN GARCIA-SANCHO, MD role: CONTACT lat: 40.96882 lon: -5.66388 hasResults: False
|
<|newrecord|> nctId: NCT06284109 id: 23-1036 briefTitle: Preoperative (Pre-amputation) Cryoanalgesia to Improve Post-amputation Phantom Limb Pain overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-12-31 date: 2024-12-31 date: 2024-02-28 date: 2024-04-23 name: The Cleveland Clinic class: OTHER name: Pacira Pharmaceuticals, Inc briefSummary: Investigators will evaluate preamputation cryoanalgesia on pain, mobility, opioid use and general physical and emotional disability using a pilot randomized trial design, to explore the amount and variability of improvement on those outcomes and to investigate the potentiality of conducting a future larger randomized controlled trial, which the investigators will assess quantitatively the benefits of cryoanalgesia. conditions: Postoperative Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Pre-Operative Patients will receive cryoanalgesia or sham cryoanalgesia before amputation. primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: All participants will receive nerve blocks with Local anesthetic. Participants will be Randomized on a 1:1 fashion to cryoanalgesia or sham cryoanalgesia, based on computer-generated codes and use random-sized blocks. Patients will not be told which group they are in. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 20 type: ESTIMATED name: Cryoanalgesia name: Sham Cryoanalgesia measure: Phantom limb pain score measure: Mobility measure: General physical and emotional disability measure: Opioid consumption measure: Residual limb pain sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06284096 id: 2023/391 briefTitle: The Personal Recovery Based Psychoeducation For Schizophrenia overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2024-06 date: 2024-06 date: 2024-02-28 date: 2024-03-07 name: Istanbul University - Cerrahpasa (IUC) class: OTHER briefSummary: This project aims to introduce a new psychoeducation program that helps individuals with schizophrenia to recover subjectively. The program's effectiveness will be evaluated through a randomized controlled research design. The goal is not only to emphasize clinical recovery but also to highlight the importance of individual recovery and promote its implementation. In this context, the following hypotheses have been formulated.
|
Research Question:
|
1) Does recovery-based psychoeducation have an impact on the subjective recovery level in individuals diagnosed with schizophrenia in remission?
|
Hypotheses:
|
H0a: Recovery-based psychoeducation does not affect the subjective recovery level in individuals diagnosed with schizophrenia in remission.
|
H0b: Recovery-based psychoeducation does not effect on psychological resilience in individuals diagnosed with schizophrenia in remission.
|
H0c: Recovery-based psychoeducation does not effect on hope in individuals diagnosed with schizophrenia in remission.
|
H1a: Recovery-based psychoeducation affects the subjective recovery level in individuals diagnosed with schizophrenia in remission.
|
H1b: Recovery-based psychoeducation has an effect on psychological resilience in individuals diagnosed with schizophrenia in remission.
|
H1c: Recovery-based psychoeducation has an effect on hope in individuals diagnosed with schizophrenia in remission. conditions: Mental Health Recovery conditions: Schizophrenia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 60 type: ESTIMATED name: Psychoeducation measure: Personal Recovery levels of individuals diagnosed with schizophrenia measure: Psychological resilience levels of individuals diagnosed with schizophrenia measure: Hope levels of individuals diagnosed with schizophrenia sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Umraniye Community Mental Health Center affiliated with the Ministry of Health. city: Istanbul state: Umraniye zip: 34760 country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
|
<|newrecord|> nctId: NCT06284083 id: Cumhuriyet University Hospital briefTitle: Measuring Various Variables in Obstructive Sleep Apnea acronym: OUAS overallStatus: COMPLETED date: 2018-12-18 date: 2021-01-15 date: 2022-02-07 date: 2024-02-28 date: 2024-02-28 name: Cumhuriyet University class: OTHER briefSummary: This study included 90 volunteer Obstructive Sleep Apnea Syndrome patients. Only 7 mL blood samples collected from patients. Some biochemicals parameters analyzed in blood serum/plasma. conditions: Obstructive Sleep Apnea-hypopnea Syndrome studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The study group consisted of 90 newly diagnosed OSAS patients who were admitted to the Clinic for Chest Diseases of the Research and Practice Hospital of Sivas Cumhuriyet University Faculty of Medicine. For the definitive diagnosis of OSAS, the patients were hospitalized overnight in the Sleep Center and polysomnography test was performed. OSAS patients, who were randomly selected without discrimination in terms of age and gender, were connected to the PSG device for one night and various measurements were taken and the values were recorded. The apnea/hypopnea index (AHI) was defined as the sum of the apnea and hypopnea number per hour of sleep. Volunteer patients were grouped into three based on apnea-hypopnea index (AHI) scores: mild OSAS (n=30; 5 ≤ AHI ≤ 13.70), moderate (n=30; 15.80 ≤ AHI ≤ 26.60) and severe (n=30; 34.10 ≤ AHI ≤ 86.30). The mean SpO2 percentages of the PSG device were measured from the fingertip with a system-defined pulse oximeter. primaryPurpose: HEALTH_SERVICES_RESEARCH masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 90 type: ACTUAL name: taking a blood sample measure: Agmatine, telomerase and trace element levels in blood serum vary depending on disease severity. measure: Polysomnographic measurement sex: ALL minimumAge: 18 Years maximumAge: 74 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sivas Cumhuriyet University city: Sivas state: Centre zip: 58140 country: Turkey lat: 39.74833 lon: 37.01611 hasResults: False
|
<|newrecord|> nctId: NCT06284070 id: 202433 briefTitle: Application of FAPI and FDG PET Imaging in Patients With Different Types of Cancer overallStatus: RECRUITING date: 2024-01-01 date: 2029-12-31 date: 2029-12-31 date: 2024-02-28 date: 2024-02-28 name: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University class: OTHER briefSummary: Cancer associated fibroblasts (CAFs) can promote tumor cell proliferation, migration, invasion, and angiogenesis through immunosuppressive effects and the production of mediators, thereby promoting tumor growth and progression. The characteristic of CAFs is high expression of fibroblast activation protein (FAP). In approximately 90% of epithelial derived tumors, FAP is highly overexpressed on the membrane of CAFs. Contrary to CAFs, FAP expression is lower or absent in normal tissues. Therefore, FAP inhibitors (FAPI) targeting FAP can overcome the limitations of 18F-2-fluoro.2-deoxy-D-glucose fluorodeoxyglucose(18F-FDG) PET imaging. But like 18F-FDG, wound healing, fibrosis, and inflammation can also uptake FAPI.. Therefore, a comparison of the performance of 18F-FDG and 18F-FAPI PET imaging in diagnosing primary and metastatic lesions of various types of cancer is conducted to evaluate the potential value of these new radiopharmaceuticals as effective alternatives to 18F-FDG, highlighting their advantages and limitations. conditions: Cancer studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 2000 type: ESTIMATED measure: Diagnostic efficacy measure: SUV sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Nuclear Medicine, Daping Hospital of Army Medical University status: RECRUITING city: Chongqing state: Chongqing zip: 400010 country: China name: Xiao Chen, Ph.D role: CONTACT phone: 15922970174 email: xiaochen229@foxmail.com name: Xiao Chen, Ph.D role: PRINCIPAL_INVESTIGATOR name: Jinju Sun, MSc role: PRINCIPAL_INVESTIGATOR lat: 29.56278 lon: 106.55278 hasResults: False
|
<|newrecord|> nctId: NCT06284057 id: CopperHealthCentre3 briefTitle: Lower Silesia Culotte Bifurcation Registry (LSCBR). acronym: LSCBR overallStatus: RECRUITING date: 2013-04-01 date: 2028-04-01 date: 2028-04-01 date: 2024-02-28 date: 2024-03-06 name: Regional Cardiology Center, The Copper Health Centre (MCZ), class: OTHER name: Department of Cardiology, Provincial Specialized Hospital in Legnica, 59-200 Legnica, Poland. briefSummary: The study aimed to evaluate the outcomes of bifurcation PCI using two techniques (Culotte vs. DK-Culotte) using data from a retrospective analysis. conditions: Safety Issues conditions: Efficacy, Self studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 400 type: ESTIMATED name: Bifurcation PCI with two stent technique Culotte Technique or Double Kiss (DK) Culotte measure: Target lesion failure (TLF) measure: MACE measure: Stent thrombosis measure: Stent restenosis sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Cardiology, Provincial Specialized Hospital in Legnica, status: RECRUITING city: Legnica state: Lower Silesia zip: 59-220 country: Poland name: Mateusz Barycki, M.D role: CONTACT phone: +48767211446 email: mateusz.barycki@gmail.com name: Piotr Rola, M.D. Ph.D role: CONTACT phone: +48767211446 email: piotr.rola@gmail.com name: Mateusz Barycki, MD role: PRINCIPAL_INVESTIGATOR name: Piotr Rola, MD PhD role: SUB_INVESTIGATOR lat: 51.21006 lon: 16.1619 facility: Department of Cardiology, The Copper Health Centre (MCZ) status: RECRUITING city: Lubin state: Lower Silesia zip: 59-300 country: Poland name: Adrian Włodarczak, Assoc Prof. role: CONTACT phone: +48768460300 email: wlodarczak.adrian@gmail.com name: Szymon Włodarczak, MD role: CONTACT phone: +4876 846 03 00 email: wlodarczak.szy@gmail.com name: Adrian Włodarczak, Assoc Prof. role: PRINCIPAL_INVESTIGATOR name: Szymon Włodarczak, MD role: SUB_INVESTIGATOR lat: 51.40089 lon: 16.20149 hasResults: False
|
<|newrecord|> nctId: NCT06284044 id: NIHR204885 briefTitle: Facilitating Safe Transition to Home for Preterm Infants - a National Database Study overallStatus: RECRUITING date: 2023-12-01 date: 2024-11-30 date: 2024-11-30 date: 2024-02-28 date: 2024-03-27 name: University Hospitals of Derby and Burton NHS Foundation Trust class: OTHER briefSummary: Preterm infants (i.e. born before 37 completed weeks of pregnancy) often require additional care and are admitted to neonatal units. Readiness for discharge home typically requires a level of physiological maturity, such that an infant is: 1) able to breathe spontaneously without additional support; 2) able to maintain body temperature; 3) able to take all nutritional requirements orally; 4) weighs ≥1700 grams and is consistently gaining weight.
|
Staying in the hospital longer than necessary can be detrimental to infants, stressful for families, and costly to the NHS. Reducing the length of stay by just one day would be meaningful to parents and could save the UK National Health Service (NHS) almost £25million per year. Currently little is known about whether, how long and why preterm infants stay in hospital beyond the point at which they are physiologically ready for discharge.
|
This study will use data from babies' medical records from the whole of England and Wales to identify the age and postmenstrual age when preterm infants reach each of the physiological barriers to discharge and identify which physiological discharge barrier requires preterm infants to remain in hospital the longest. The study will quantify the difference between the time preterm infants become physiologically ready for discharge and actual discharge home and describe factors associated with extended stays. conditions: Premature Birth studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 250000 type: ESTIMATED measure: Age and postmenstrual age when each of three physiological barriers are reached measure: Final barrier to discharge home measure: Number of days in hospital after surpassing all physiological discharge barriers sex: ALL minimumAge: 22 Weeks maximumAge: 36 Weeks stdAges: CHILD facility: University Hospitals of Derby and Burton status: RECRUITING city: Derby state: Derbyshire zip: DE22 3DT country: United Kingdom name: Janine Abramson, BSc Hon role: CONTACT phone: 01332 724690 email: janine.abramson@nottingham.ac.uk lat: 52.92277 lon: -1.47663 hasResults: False
|
<|newrecord|> nctId: NCT06284031 id: Brachy Study briefTitle: Cervical Cancer Brachytherapy With Interstitial Needles in 3 Fractions overallStatus: RECRUITING date: 2023-06-26 date: 2026-06 date: 2026-12 date: 2024-02-28 date: 2024-02-28 name: National University Hospital, Singapore class: OTHER briefSummary: Aim To determine the feasibility and safety of 3 fractions of high dose rate (HDR) brachytherapy with interstitial needles for cervical cancer in the outpatient setting
|
Primary objective To determine the clinical outcome (2-yr local control rate, loco-regional control rate, progression free survival and overall survival)
|
Secondary objective To determine the long-term toxicities of this regimen based on CTCAE v5 conditions: Cervical Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 56 type: ESTIMATED name: 3 fractions HDR brachytherapy measure: Local control rate measure: Loco-regional control rate measure: Progression-free survival (PFS) measure: Overall survival (OS) measure: Long term toxicities sex: FEMALE minimumAge: 21 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National University Hospital status: RECRUITING city: Singapore zip: 119074 country: Singapore name: Fatin Aliyah, BSc role: CONTACT phone: +6581005851 email: fatin_hussin@nuhs.edu.sg name: Syadwa Abdul Shukor, MD role: SUB_INVESTIGATOR name: Yiat Horng Leong, MD role: SUB_INVESTIGATOR name: Shing Fung Lee, MD role: SUB_INVESTIGATOR name: Michelle Tseng, MD role: SUB_INVESTIGATOR lat: 1.28967 lon: 103.85007 hasResults: False
|
<|newrecord|> nctId: NCT06284018 id: postnatal low back pain briefTitle: Effect of Progressive Muscle Relaxation Exercises Versus Pilates Exercises on Postnatal Low Back Pain overallStatus: NOT_YET_RECRUITING date: 2024-02-24 date: 2024-12-31 date: 2024-12-31 date: 2024-02-28 date: 2024-02-29 name: Cairo University class: OTHER briefSummary: This study was conducted to compare between the effect of progressive muscle relaxation exercises and the effect of pilates exercises on postnatal low back pain conditions: Low Back Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: intervention The design of the study was randomized controlled study. The patients were divided randomly into two equal groups (A\&B). Group A consisted of thirty postnatal women. They were treated by progressive muscle relaxation exercises three times per week for 4 weeks. Group B consisted of thirty postnatal women. They were treated by pilates exercises three times per week for 4 weeks. primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Progressive Muscle Relaxation Exercises name: Pilates Exercises measure: Pressure Algometer measure: Oswestry Disability Index sex: FEMALE minimumAge: 25 Years maximumAge: 35 Years stdAges: ADULT facility: faculty of physical therapy: Cairo university city: Giza zip: 12662 country: Egypt lat: 30.00808 lon: 31.21093 hasResults: False
|
<|newrecord|> nctId: NCT06284005 id: MOTU ATP - Studio clinico briefTitle: Multicentre Interventional Pilot Study on the Evaluation of the Functionality, Safety and Reliability of a New Robotic Prosthesis for the Lower Limb at the Transfemoral Level acronym: MOTU-ATP overallStatus: COMPLETED date: 2020-07-27 date: 2022-11-10 date: 2022-12-22 date: 2024-02-28 date: 2024-02-28 name: Fondazione Don Carlo Gnocchi Onlus class: OTHER briefSummary: The goal of this multicenter interventional pilot is to verify the functionality of a prosthesis for trans-femoral amputees.
|
The main question it aims to answer are:
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.